Axovant Gene Therapies logo

AXGT - Axovant Gene Therapies Share Price

$2.35 0.0  0.9%

Last Trade - 30/03/20

Sector
Healthcare
Size
Small Cap
Market Cap £69.7m
Enterprise Value £59.6m
Revenue £n/a
Position in Universe 4042nd / 6308
Bullish
Bearish
Unlock AXGT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AXGT Revenue Unlock AXGT Revenue

Net Income

AXGT Net Income Unlock AXGT Revenue

Normalised EPS

AXGT Normalised EPS Unlock AXGT Revenue

PE Ratio Range

AXGT PE Ratio Range Unlock AXGT Revenue

Dividend Yield Range

AXGT Dividend Yield Range Unlock AXGT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AXGT EPS Forecasts Unlock AXGT Revenue
Profile Summary

Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.

Directors
Last Annual March 31st, 2019
Last Interim December 31st, 2019
Incorporated October 31, 2014
Public Since June 11, 2015
No. of Shareholders: 2
No. of Employees: 57
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,823,005
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AXGT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AXGT
Upcoming Events for AXGT
Similar to AXGT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.